Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).

• Status: Recruiting
• Trial end date: 2031-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To find out if contrast enhanced ultrasound (CEUS) can be used to determine if patients receiving combined ICI therapy for triple negative breast cancer (TNBC) are responding to treatment earlier than standard of care MR or CT.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Milton S. Hershey Medical Center

Criteria

Inclusion Criteria:

• Willingness and ability to sign and date the study-specific informed consent form.

• Stated willingness to comply with all study procedures and attend all study visits to the best of his or her ability for the duration of the study.

• Age greater than 18yo.

• Stage I-III TNBC or stage IV TNBC with intact breast primary.

• Planned combined ICI therapy as per SoC by treating oncologist.

Exclusion Criteria:

• Other clinical trials are not excluded but participation must be cleared with the other clinical trial PIs.

• Patients not suitable to undergo contrast enhanced ultrasound (i.e., pregnant women, known allergy to eggs, or a past allergic reaction to sonographic contrast or its components, such as polyethylene glycol (PEG))